Clinical trial · Observational

Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)

NCT02662920CI-TRIAL-00033535completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Prevalence and prognostic significance of polypharmacy has not been evaluated in adults undergoing treatment for AML. Investigating the significance of polypharmacy in this population may help improve patient assessment and provide an opportunity to design simple interventions to minimize unnecessary morbidity associated with treatment.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
ACUTE MYELOGENOUS LEUKEMIA	Acute Myeloid Leukemia	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
No Intervention	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
Prevalence of polypharmacy in adults ≥60 years of age hospitalized for treatment of newly diagnosed AML
timeFrame
Day 1 (admission)
description
Number of medications at baseline
measure
Prevalence of polypharmacy in adults ≥60 years of age hospitalized for treatment of newly diagnosed AML
timeFrame
Through hospitilization, an average of 30 days
description
Number of medications at discharge

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 60 Years

Show eligibility criteria text

Inclusion Criteria:

* Hospitalized between January 2004 and December 2009 with newly diagnosed AML
* Age ≥60 years at the time of diagnosis
* Received treatment while hospitalized for AML

Exclusion Criteria:

* 30-day mortality data unavailable

References

Publications (0)

Data not yet available

No reference posted for this study.